FY2025 · ended Dec 31, 2025 · Revenue $75,730, +65.6% YoY · Filed Mar 18, 2026
Aclarion, Inc. (ACON) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $75,730 and a net loss of $7.2 million. Free cash flow was -$7.2 million.
Revenue (TTM)
$98,560
+46.1% vs year-ago TTM
Net income (TTM)
$-10.11M
-37.9% vs year-ago TTM
Operating cash flow (TTM)
$-8.95M
-38.5% vs year-ago TTM
Free cash flow (TTM)
$-8.96M
EPS (TTM)
$-5.13
+76.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.28M
+291.9% vs prior year
Net cash
—
Operating margin
-10789.2%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- ACON (Nasdaq), ACONW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Broomfield, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1635077
- Former names
- Nocimed, Inc. (until Oct 26, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $75,730 | $45,724 | $75,404 | $60,444 |
| Operating income | -$7.1M | -$5.5M | -$4.9M | -$5.6M |
| Net income | -$7.2M | -$7.0M | -$4.9M | -$7.1M |
| Diluted EPS | -$13.61 | -$7,478.90 | -$79,782.00 | -$19.61 |
| Operating cash flow | -$7.2M | -$5.3M | -$3.6M | -$4.9M |
| Free cash flow | -$7.2M | -$5.3M | — | — |
| Total assets | $13.7M | $2.1M | $2.5M | $2.9M |
| Total liabilities | $837,287 | — | — | — |
| Stockholders' equity | $12.8M | $970,057 | -$727,995 | $2.2M |
| Cash and investments | $12.0M | $453,661 | $1.0M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 22, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Mar 19, 2026 | Mar 19, 2026 |
All 276 Aclarion, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.